DiaSys Corporation (AMEX:DYX) a global healthcare products company, announced today that it has signed a three year exclusive distribution agreement with DICIPA in Mexico. The agreement guarantees minimum purchase orders of $11.75 million for the Company's fully integrated parasitology workstations and consumable products over the three year period. DICIPA, which was founded in 1979, also represents Beckman Coulter and Dade Behring.

"Our three year distribution agreement in Mexico is a significant achievement for DiaSys and proves our sales strategy in Latin America, following our announcement in Venezuela earlier this month. The fully integrated parasitology system, completed in the first calendar quarter of this year, is the only system of its kind and without competition. We received a major commitment from the largest medical distributor of diagnostic products in Mexico. We look forward to the continued roll out of the product line throughout Latin America as we position for sales into rest of the world markets," said Gregory Witchel, Chief Executive Officer.

Jose Puig, Sales Manager Latin America stated, "The agreement in Mexico provides DiaSys with a strong foothold into Latin American markets and is a strong base on which to grow sales in the future. We will extend our sales initiative throughout the territory during 2006."

DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation.

This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company.

Back